I am a Ph.D. researcher in Pharmaceutical Sciences with specialized expertise in nanotechnology-based drug delivery systems, Quality by Design (QbD) approaches, and translational pharmacological research. My doctoral work centers on the development of innovative therapeutic strategies for Oral Submucous Fibrosis (OSMF), including the rational design of nanoformulations and their preclinical evaluation using robust in vitro and in vivo models. A key contribution of my research is the establishment of an arecoline-induced mouse model for OSMF, enabling a mechanistic understanding of disease progression and therapeutic screening. My broader research interests include nanomedicine, phytopharmaceutical development, experimental pharmacology, and advanced biomaterials for drug delivery applications. I have authored multiple peer-reviewed publications in high-impact international journals in the fields of drug delivery, oral pathology, and nanomedicine. I am actively seeking opportunities to advance translational research in nanotherapeutics to improve clinical outcomes for oral and systemic diseases.